David Schull

Aspen’s personalised Parkinson’s cell therapy to advance to Phase III clinicaltrialsarena.com/news/aspens-pe…

Our team attended the 48th Annual Carrell Krusen Neuromuscular Symposium, an immersive clinical education experience designed for multidisciplinary care teams supporting patients with rare and complex neuromuscular conditions. The symposium focuses on disorders such as hereditary muscular dystrophies, motor neuron diseases, neuroimmunologic neuropathies, and rare diseases affecting muscle and nerve, like Lambert-Eaton myasthenic syndrome (LEMS) and Duchenne muscular dystrophy (DMD).

When a loved one is diagnosed with a rare disease, caregiving often becomes an integral part of who you are. Bill, a father and caregiver to a son with Duchenne muscular dystrophy (DMD), shares his personal journey of navigating the emotional challenges of this role. Listen to his story on #CatalystConvos: catalystpharma.com/catalyst-convos

At our inaugural Catalyst Advocacy Scholars Summit (CASS), we turned the spotlight on our scholars at the start of the week, asking what they hoped to discover and what drew them to patient advocacy. Their curiosity, insight, and passion for patient communities were clear from day one. Watch to hear directly from these future healthcare providers and patient advocates as they share their early reflections: ir.catalystpharma.com/news/news-deta…. #CASS2026

"Gastrointestinal cancers are expected to double worldwide by 2050..." The data points to rising lifestyle-related risk factors—but also highlights something equally important: the need to identify disease earlier, before it progresses: lnkd.in/gxNaHKsK

Watch any pharmaceutical commercial and you’ll see the pattern: A promise of relief, then a rapid-fire list of risks and potentially deadly side effects. Our research focuses on fibroblasts and their biological role by studying how they interact with the immune system. Our fibroblast cells restore balance rather than suppress it NASDAQ: FBLG #FibroBiologics #MedicalInnovation #ClinicalResearch

For 100+ years, medicine has focused on symptom management. Cell-based therapies aim to address biology itself. NASDAQ: FBLG #FibroBiologics #CellTherapy

I’m not here to second guess anyone’s home work, but @Bengals fans, please read and learn how the rest of the @NFL operates by playing Chess ♟️ not Checkers. si.com/nfl/bengals/on…

20M people worldwide live with spinal cord injury, with ~$5M in lifetime costs per patient. On the Russo Edge Podcast, @SolomonsWisdom speaks with Adrien Cohen of SCI Ventures about the scale of the challenge and why innovation targeting the nervous system could also impact ALS, MS, stroke, and brain injury. Listen now: bit.ly/4s8080L 🎧 Apple Podcasts: apple.co/47bHpcy 🎥 YouTube: bit.ly/4rEfmuR #SpinalCordInjury #Neuroscience #ALS #MultipleSclerosis #Stroke #Podcast

Today, Coya announced the publication of a research study demonstrating the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia (#FTD). Dr. Fred Grossman, Chief Medical Officer at Coya said, “We believe these biomarker data coupled with the clinical and lab results of the clinical study in FTD provide additional evidence supporting the development of biologic combination therapies that enhance the function of regulatory T cells and target inflammation in FTD, ALS and other neurodegenerative diseases of high unmet need.” For more details: businesswire.com/news/home/2026…

Stopped for a pic at the Fischli and Weiss “Rock on top of Another Rock”, which evokes the beauty of pushing limits. An inspirational idea applicable to our regenerative medicine mission. Thanks for hosting us in Basel, Roche! $LCTX

𝐀𝐈 𝐍𝐞𝐰𝐬: Checking in with @MenloVentures' Partner @grgyap to get his take on the latest trends in AI in healthcare. Full video: biotechtv.com/post/menlo-ven…

Despite evidence since 2019 that many recover without full abstinence, many programs still overlook reduction-focused goals. It’s time to broaden how we define #AUD recovery. bit.ly/43PYjuT #AlcoholUseDisorder #RecoveryScience

@AndrewE_Dunn @endpts Indeed!

Some GREAT news here at @endpts today: so excited to be working with and learning from 2 fantastic journalists in Karen Weintraub, formerly the enterprise editor at USA Today, and Kevin Miller, a longtime Bloomberg editor. More on our own news: endpoints.news/karen-weintrau…

I'll be covering this morning's @ChinaSelect hearing on China's ascension in the pharma industry, from APIs to licensing deals. We're underway. Here are the witnesses:

J&J pulls out of NYC biotech incubator as it shrinks locations - endpoints.news/jj-pulls-out-o…

New renal disease biotech R1 Therapeutics raises $77.5M for Phase 2b. endpoints.news/new-renal-dise…

Aspen’s personalized Parkinson’s therapy shows early promise endpoints.news/aspens-persona…

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy businesswire.com/news/home/2026…